Following fast-fail model, Quench passes on hard-to-drug inflammation target gasdermin D 

Atlas-incubated Quench became the latest example of the VC’s ethos of failing quickly and transparently after announcing it had auctioned off its IP for small molecule inhibitors of hard-to-drug inflammation target gasdermin D.

In a Twitter thread posted Tuesday, Quench Bio said it would wind down operations and return capital to investors because it failed to “identify a potent, selective chemical series to progress — which was our goal by Q1 2021,” despite running “a thorough discovery campaign with several approaches using multiple, orthogonal technologies.” ...